Literature DB >> 34748286

Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome.

Serena Colafrancesco1, Cristiana Barbati1, Roberta Priori2, Erisa Putro1, Federico Giardina1, Angelica Gattamelata1, Benedetta Monosi1, Tania Colasanti1, Alessandra Ida Celia1, Bruna Cerbelli1, Carla Giordano1, Susanna Scarpa1, Massimo Fusconi1, Giulio Cavalli3, Onorina Berardicurti4, Saviana Gandolfo5, Saba Nayar6, Francesca Barone6, Roberto Giacomelli7, Salvatore De Vita5, Cristiano Alessandri1, Fabrizio Conti1.   

Abstract

OBJECTIVE: Salivary gland epithelial cells (SGECs) are key cellular drivers in the pathogenesis of primary Sjögren's syndrome (SS); however, the mechanisms sustaining SGEC activation in primary SS remain unclear. We undertook this study to determine the role of autophagy in the survival and activation of SGECs in primary SS.
METHODS: Primary SGECs isolated from the minor SGs of patients with primary SS or sicca syndrome were evaluated by flow cytometry, immunoblotting, and immunofluorescence to assess autophagy (autophagic flux, light chain 3 IIB [LC3-IIB], p62, LC3-IIB+/lysosome-associated membrane protein 1 [LAMP-1] staining), apoptosis (annexin V/propidium iodide [PI], caspase 3), and activation (intercellular adhesion molecule, vascular cell adhesion molecule). Focus score and germinal center presence were assessed in the SGs from the same patients to assess correlation with histologic severity. Human SG (HSG) cells were stimulated in vitro with peripheral blood mononuclear cells (PBMCs) and serum from primary SS patients in the presence or absence of autophagy inhibitors to determine changes in autophagy and epithelial cell activation.
RESULTS: SGECs from primary SS patients (n = 24) exhibited increased autophagy (autophagic flux [P = 0.001]; LC3-IIB [P = 0.02]; p62 [P = 0.064]; and as indicated by LC3-IIB/LAMP-1+ staining), increased expression of antiapoptotic molecules (Bcl-2 [P = 0.006]), and reduced apoptosis (annexin V/PI [P = 0.002]; caspase 3 [P = 0.057]), compared to samples from patients with sicca syndrome (n = 16). Autophagy correlated with histologic disease severity. In vitro experiments on HSG cells stimulated with serum and PBMCs from primary SS patients confirmed activation of autophagy and expression of adhesion molecules, which was reverted upon pharmacologic inhibition of autophagy.
CONCLUSION: In primary SS SGECs, inflammation induces autophagy and prosurvival mechanisms, which promote SGEC activation and mirror histologic severity. These findings indicate that autophagy is a central contributor to the pathogenesis of primary SS and a new therapeutic target.
© 2021 American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34748286     DOI: 10.1002/art.42018

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  4 in total

1.  Impaired GATE16-mediated exocytosis in exocrine tissues causes Sjögren's syndrome-like exocrinopathy.

Authors:  Akiko Suzuki; Chihiro Iwaya; Kenichi Ogata; Hiroki Yoshioka; Junbo Shim; Isei Tanida; Masaaki Komatsu; Norihiro Tada; Junichi Iwata
Journal:  Cell Mol Life Sci       Date:  2022-05-20       Impact factor: 9.261

2.  Vitamin D Deficiency in Primary Sjögren's Syndrome: Association with Clinical Manifestations and Immune Activation Markers.

Authors:  Panagiotis Athanassiou; Clio Mavragani; Lambros Athanassiou; Ifigenia Kostoglou-Athanassiou; Michael Koutsilieris
Journal:  Mediterr J Rheumatol       Date:  2022-03-31

Review 3.  Autophagy in Rheumatic Diseases: Role in the Pathogenesis and Therapeutic Approaches.

Authors:  Alessandra Ida Celia; Serena Colafrancesco; Cristiana Barbati; Cristiano Alessandri; Fabrizio Conti
Journal:  Cells       Date:  2022-04-15       Impact factor: 7.666

4.  Alterations of m6A RNA methylation regulators contribute to autophagy and immune infiltration in primary Sjögren's syndrome.

Authors:  Linlin Cheng; Haolong Li; Haoting Zhan; Yongmei Liu; Xiaomeng Li; Yuan Huang; Li Wang; Fengchun Zhang; Yongzhe Li
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.